Esophageal Adenocarcinoma
نویسندگان
چکیده
منابع مشابه
Chemoprevention of esophageal adenocarcinoma.
The incidence of esophageal adenocarcinoma (EAC) is rising rapidly in Western countries, and effective chemoprevention for this malignancy is lacking. Endoscopic surveillance of patients with Barrett's esophagus is currently employed to diagnose EAC at earlier stages, but this strategy has several limitations. Non-steroidal anti-inflammatory drugs and proton pump inhibitors are the most promisi...
متن کاملEpidemiology of esophageal adenocarcinoma.
The incidence of esophageal adenocarcinoma has risen rapidly over the past 25 years in the United States as well as in several Western European countries. This increase had been most dramatic among white males. The majority of these cancers arise from a background of premalignant Barrett esophagus. However, less than 10% of the patients with esophageal adenocarcinoma were known to have Barrett ...
متن کاملvitiligo associated with esophageal adenocarcinoma
vitiligo is a disease that results in depigmented areas in the skin. it may develop at any age but the average age at onset is 20 years. association of vitiligo and melanoma has been commonly reported, but malignancies other than melanoma have been rarely associated with vitiligo. we report a 73‑year‑old patient with new onset vitiligo who developed esophageal adenocarcinoma in the following ye...
متن کاملClinical biomarkers in esophageal adenocarcinoma.
This review describes genetic and molecular changes related to adenocarcinoma of the esophagus and gastroesophageal junction (GEJ) with emphasis on prognostic value and possibilities for targeted therapy in clinical setting. The progression of Barrett's esophagus to adenocarcinoma has been the focus of particular scrutiny, and a number of potential tissue and serum-based disease biomarkers have...
متن کاملCurrent Therapy for Esophageal Adenocarcinoma
Esophageal adenocarcinoma (EAC) affects approximately 17,000 individuals per year in the United States, is increasing in incidence, and is associated with an exceptionally high mortality rate. 1, 2 Overall five-year survival despite aggressive treatment in large, multidisciplinary oncology centers ranges between 15 and 25%. Poor outcome in patients with EAC is reflective of both deficiencies in...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Clinical Gastroenterology and Hepatology
سال: 2006
ISSN: 1542-3565
DOI: 10.1016/j.cgh.2006.07.021